InflaRx (IFRX) Beginning Cash Balance (2017 - 2026)
InflaRx (IFRX) posted Beginning Cash Balance of $18.8 million for Q1 2026, down 2.96% sequentially from $19.3 million in Q1 2025, and down 2.96% YoY from $19.3 million in Q1 2025.
InflaRx (IFRX) Beginning Cash Balance (2017 - 2026) Analysis & Trends
InflaRx has reported Beginning Cash Balance for 10 years, with the latest figure at $18.8 million in Q1 2026.
- Quarterly Beginning Cash Balance fell 2.96% year-over-year to $18.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (down 2.96% YoY) and the FY2025 annual result came in at $20.8 million, up 50.24% from the prior year.
- Beginning Cash Balance eased to $18.8 million in Q1 2026 per IFRX's latest filing, from $19.3 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $29.5 million in Q1 2022 and troughed at $13.9 million in Q1 2024.
- A 5-year average of $19.8 million and a median of $18.8 million in 2026 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2023 and 2025: Beginning Cash Balance sank 40.74% in 2023, then soared 39.36% in 2025.
- Over 5 years, Beginning Cash Balance stood at $29.5 million in 2022, then sank by 40.74% to $17.5 million in 2023, then decreased by 20.55% to $13.9 million in 2024, then jumped by 39.36% to $19.3 million in 2025, then fell by 2.96% to $18.8 million in 2026.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered $18.8 million, $19.3 million, and $13.9 million for Q1 2026, Q1 2025, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.76 Mn |
| Mar 31, 2026 | 18.76 Mn |
| Mar 31, 2025 | 19.33 Mn |
| Mar 31, 2025 | 19.33 Mn |
| Mar 31, 2024 | 13.87 Mn |
| Mar 31, 2024 | 13.87 Mn |
| Mar 31, 2023 | 17.46 Mn |
| Mar 31, 2023 | 17.46 Mn |
| Mar 31, 2022 | 29.46 Mn |
| Mar 31, 2022 | 29.46 Mn |
| Mar 31, 2021 | 31.32 Mn |
| Mar 31, 2021 | 31.32 Mn |
| Mar 31, 2020 | 36.57 Mn |
| Mar 31, 2020 | 36.57 Mn |
| Mar 31, 2019 | 62.95 Mn |
| Mar 31, 2019 | 62.95 Mn |
| Sep 30, 2018 | -130.27 |
| Sep 30, 2018 | -130.27 |
| Mar 31, 2018 | 151.46 Mn |
| Mar 31, 2018 | 151.46 Mn |